After Hours Most Active for Mar 13, 2025 : HTZ, NVDA, HOOD, TD, HPE, PRMB, AVGO, AAPL, BAM, SLF, EW, TSLA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 13 2025
0mins
Source: NASDAQ.COM
NASDAQ 100 After Hours Performance: The NASDAQ 100 is up by 43.03 points to 19,268.51 with a total after-hours trading volume of over 101 million shares, featuring active stocks like Hertz, NVIDIA, and Robinhood showing positive movements or stability.
Stock Recommendations and Forecasts: Several companies including NVIDIA, Robinhood, and Broadcom have received multiple upward revisions in their earnings forecasts, with current recommendations generally falling within the "buy range" according to Zacks.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EW?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EW
Wall Street analysts forecast EW stock price to rise
24 Analyst Rating
16 Buy
8 Hold
0 Sell
Moderate Buy
Current: 79.330
Low
84.00
Averages
96.52
High
105.00
Current: 79.330
Low
84.00
Averages
96.52
High
105.00
About EW
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Edwards Lifesciences Q4 2025 Earnings Call Insights
- Strong Sales Growth: Edwards Lifesciences reported Q4 2025 sales of $1.57 billion, reflecting an 11.6% year-over-year increase, demonstrating robust market demand and execution in structural heart therapies, which is expected to drive sustained future performance.
- Increased Earnings Guidance: Management raised the 2026 earnings per share (EPS) guidance to $2.90 to $3.05, indicating confidence in the company's future profitability, particularly driven by the TAVR and TMTT product lines.
- Accelerated Product Innovation: The launch of new products like SAPIEN M3 and next-gen PASCAL is projected to generate TMTT sales of $740 to $780 million in 2026, further solidifying the company's leadership position in the heart valve treatment market.
- Market Strategy Adjustments: The company increased market access spending by $112 million in Q4 to address competition and market demand, showcasing its agility in responding to the rapidly changing medical device landscape.
See More
Halper Sadeh LLC Investigates Edwards Lifesciences for Potential Fiduciary Breaches
- Investigation Context: Halper Sadeh LLC is investigating whether certain officers and directors of Edwards Lifesciences Corporation (NYSE: EW) breached their fiduciary duties to shareholders, which could impact corporate governance and shareholder rights.
- Shareholder Rights Protection: Long-term shareholders of Edwards may have the opportunity to seek corporate governance reforms, return of funds, or court-approved financial incentives, directly affecting investment returns and company transparency.
- Legal Fee Arrangement: The firm will handle the case on a contingent fee basis, meaning shareholders will not be responsible for out-of-pocket legal fees or expenses, reducing the financial risk of participation and encouraging more shareholders to get involved.
- Importance of Participation: Shareholder involvement can improve the company's policies, practices, and oversight mechanisms, thereby enhancing transparency and management effectiveness, ultimately contributing to increased shareholder value.
See More
Edwards Lifesciences Q4 Earnings Analysis
- Earnings Performance: Edwards Lifesciences reported Q4 earnings of 58 cents per share, missing the 62 cents consensus, yet revenue of $1.57 billion exceeded the $1.54 billion target, indicating resilience in revenue growth despite the earnings miss.
- Stock Price Reaction: Following the earnings report, EW's stock rose over 2%, suggesting investor confidence in the company's future prospects, which may reflect a market focus on revenue growth rather than earnings shortfalls.
- Options Market Dynamics: In the options market, put implied volatility is higher than call implied volatility, indicating investor concern over downside risks, while call implied volatility rises at upper boundaries, reflecting demand for upside potential, suggesting expectations of future volatility.
- Future Price Expectations: The Black-Scholes model anticipates that Edwards Lifesciences stock will trade between $74 and $82.91 by the March 20 expiration, providing a framework for traders to strategize based on market expectations for future price movements.
See More
Edwards Lifesciences (EW) Earnings Transcript
See More
Edwards Lifesciences Q4 2025 Earnings Report
- Earnings Highlights: Edwards Lifesciences reported a Q4 2025 non-GAAP EPS of $0.58, missing estimates by $0.04, while revenue reached $1.57 billion, a 13.8% year-over-year increase, exceeding expectations by $30 million, indicating strong market performance.
- Cash Position: As of December 31, 2025, the company held approximately $3.0 billion in cash and cash equivalents against total debt of about $600 million, demonstrating solid financial health that supports future investments and expansion.
- Growth Outlook: Edwards has increased confidence in achieving its 2026 sales growth rate guidance of 8% to 10%, with EPS expectations ranging from $2.90 to $3.05, reflecting an optimistic view of future performance.
- Q1 Projections: The company projects total sales for Q1 2026 to be between $1.55 billion and $1.63 billion, with adjusted EPS of $0.70 to $0.76, showcasing ongoing growth potential and market demand.
See More
Stocks Climb Higher as Bull Market Continues
- Market Sentiment: Bulls have regained control of the market following previous concerns over artificial intelligence, leading to a positive outlook for risky assets, particularly in the tech sector.
- Ongoing Rally: The rally in real assets continues as investors anticipate a series of important economic data releases in the coming days.
See More
Edwards Lifesciences Q4 2025 Earnings Call Insights
- Strong Sales Growth: Edwards Lifesciences reported Q4 2025 sales of $1.57 billion, reflecting an 11.6% year-over-year increase, demonstrating robust market demand and execution in structural heart therapies, which is expected to drive sustained future performance.
- Increased Earnings Guidance: Management raised the 2026 earnings per share (EPS) guidance to $2.90 to $3.05, indicating confidence in the company's future profitability, particularly driven by the TAVR and TMTT product lines.
- Accelerated Product Innovation: The launch of new products like SAPIEN M3 and next-gen PASCAL is projected to generate TMTT sales of $740 to $780 million in 2026, further solidifying the company's leadership position in the heart valve treatment market.
- Market Strategy Adjustments: The company increased market access spending by $112 million in Q4 to address competition and market demand, showcasing its agility in responding to the rapidly changing medical device landscape.
See More
Halper Sadeh LLC Investigates Edwards Lifesciences for Potential Fiduciary Breaches
- Investigation Context: Halper Sadeh LLC is investigating whether certain officers and directors of Edwards Lifesciences Corporation (NYSE: EW) breached their fiduciary duties to shareholders, which could impact corporate governance and shareholder rights.
- Shareholder Rights Protection: Long-term shareholders of Edwards may have the opportunity to seek corporate governance reforms, return of funds, or court-approved financial incentives, directly affecting investment returns and company transparency.
- Legal Fee Arrangement: The firm will handle the case on a contingent fee basis, meaning shareholders will not be responsible for out-of-pocket legal fees or expenses, reducing the financial risk of participation and encouraging more shareholders to get involved.
- Importance of Participation: Shareholder involvement can improve the company's policies, practices, and oversight mechanisms, thereby enhancing transparency and management effectiveness, ultimately contributing to increased shareholder value.
See More
Edwards Lifesciences Q4 Earnings Analysis
- Earnings Performance: Edwards Lifesciences reported Q4 earnings of 58 cents per share, missing the 62 cents consensus, yet revenue of $1.57 billion exceeded the $1.54 billion target, indicating resilience in revenue growth despite the earnings miss.
- Stock Price Reaction: Following the earnings report, EW's stock rose over 2%, suggesting investor confidence in the company's future prospects, which may reflect a market focus on revenue growth rather than earnings shortfalls.
- Options Market Dynamics: In the options market, put implied volatility is higher than call implied volatility, indicating investor concern over downside risks, while call implied volatility rises at upper boundaries, reflecting demand for upside potential, suggesting expectations of future volatility.
- Future Price Expectations: The Black-Scholes model anticipates that Edwards Lifesciences stock will trade between $74 and $82.91 by the March 20 expiration, providing a framework for traders to strategize based on market expectations for future price movements.
See More
Edwards Lifesciences (EW) Earnings Transcript
See More
Edwards Lifesciences Q4 2025 Earnings Report
- Earnings Highlights: Edwards Lifesciences reported a Q4 2025 non-GAAP EPS of $0.58, missing estimates by $0.04, while revenue reached $1.57 billion, a 13.8% year-over-year increase, exceeding expectations by $30 million, indicating strong market performance.
- Cash Position: As of December 31, 2025, the company held approximately $3.0 billion in cash and cash equivalents against total debt of about $600 million, demonstrating solid financial health that supports future investments and expansion.
- Growth Outlook: Edwards has increased confidence in achieving its 2026 sales growth rate guidance of 8% to 10%, with EPS expectations ranging from $2.90 to $3.05, reflecting an optimistic view of future performance.
- Q1 Projections: The company projects total sales for Q1 2026 to be between $1.55 billion and $1.63 billion, with adjusted EPS of $0.70 to $0.76, showcasing ongoing growth potential and market demand.
See More
Stocks Climb Higher as Bull Market Continues
- Market Sentiment: Bulls have regained control of the market following previous concerns over artificial intelligence, leading to a positive outlook for risky assets, particularly in the tech sector.
- Ongoing Rally: The rally in real assets continues as investors anticipate a series of important economic data releases in the coming days.
See More
